Medical Management of Stable Coronary Artery Disease

被引:0
|
作者
Pflieger, Matthew [1 ]
Winslow, Bradford T. [2 ,3 ]
Mills, Kyle [5 ]
Dauber, Ira M. [4 ]
机构
[1] Clin Family Hlth Serv, Denver, CO 80221 USA
[2] Swedish Family Med Residency Program, Littleton, CO USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] S Denver Cardiol Associates, Denver, CO USA
[5] Bend Mem Clin, Bend, OR USA
关键词
CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HIGH-RISK; SECONDARY PREVENTION; HEART-DISEASE; BETA-BLOCKERS; METAANALYSIS; MORTALITY; EFFICACY;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
All patients with stable coronary artery disease require medical therapy to prevent disease progression and recurrent cardiovascular events. Three classes of medication are essential to therapy: lipid-lowering, antihypertensive, and antiplatelet agents. Lipid-lowering therapy is necessary to decrease low-density lipoprotein cholesterol to a target level of less than 100 mg per dL, and physicians should consider a goal of less than 70 mg per dL for very high-risk patients. Statins have demonstrated clear benefits in morbidity and mortality in the secondary prevention of coronary artery disease; other medications that can be used in addition to statins to lower cholesterol include ezetimibe, fibrates, and nicotinic acid. Blood pressure therapy for patients with coronary artery disease should start with beta blockers and angiotensin-converting enzyme inhibitors. If these medications are not tolerated, calcium channel blockers or angiotensin receptor blockers are acceptable alternatives. Aspirin is the first-line antiplatelet agent except in patients who have recently had a myocardial infarction or undergone stent placement, in which case clopidogrel is recommended. Anginal symptoms of coronary artery disease can be treated with beta blockers, calcium channel blockers, nitrates, or any combination of these. Familiarity with these medications and with the evidence supporting their use is essential to reducing morbidity and mortality in patients with coronary artery disease. (Am Fam Physician. 2011;83 (7):819-826. Copyright (C) 2011 American Academy of Family Physicians.)
引用
收藏
页码:819 / 826
页数:8
相关论文
共 50 条
  • [31] Stable coronary artery disease
    Scherger, JE
    AMERICAN FAMILY PHYSICIAN, 1998, 57 (05) : 945 - 945
  • [33] Stable Coronary Artery Disease in Hypertension: Diagnosis, Medical Therapy and Revascularisation
    Elsner, D.
    JOURNAL FUR HYPERTONIE, 2008, 12 (03): : 14 - 18
  • [35] Medical Therapy Versus Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease
    Arbab-Zadeh, Armin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (06) : 528 - 529
  • [36] Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease
    Kim, Jitae A.
    Kim, Seulgi E.
    El Hachem, Karim
    Virk, Hafeez Ul Hassan
    Alam, Mahboob
    Virani, Salim S.
    Sharma, Samin
    House, Andrew
    Krittanawong, Chayakrit
    AMERICAN JOURNAL OF MEDICINE, 2023, 136 (12): : 1147 - 1159
  • [37] How stable is stable coronary artery disease?
    Konigstein, Maayan
    Ben-Yehuda, Ori
    CORONARY ARTERY DISEASE, 2017, 28 (08) : 632 - 633
  • [38] MEDICAL MANAGEMENT OF CORONARY ARTERY DISEASE - A RESUME OF ITS PHARMACOLOGY
    CALESNICK, B
    ANGIOLOGY, 1963, 14 (01) : 17 - &
  • [39] Medical management of heart failure secondary to coronary artery disease
    Challapalli, S
    Bonow, RO
    Gheorghiade, M
    CORONARY ARTERY DISEASE, 1998, 9 (10) : 659 - 674
  • [40] Impact of myocardial perfusion and coronary calcium on medical management for coronary artery disease
    Hijazi, Waseem
    Feng, Yuanchao
    Southern, Danielle A.
    Chew, Derek
    Filipchuk, Neil
    Har, Bryan
    James, Matthew
    Wilton, Stephen
    Slomka, Piotr J.
    Berman, Daniel
    Miller, Robert J. H.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2023, : 482 - 490